Patients with duodenal ulcer have lower levels of serum cholesterol compared to other dyspeptic patients independently of Helicobacter pylori status

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 8, 2008, Pages 922-928

  Karpouza, Angeliki ^a   Samouilidou, Elisabeth ^a   Karagiannis, Stefanos ^a   Kostopoulou, Vasiliki ^a   Sotiropoulou, Maria ^a   Roma, Eleftheria ^b   Petraki, Kalliopi ^c   Michopoulos, Spyros ^a,d  

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Apolipoprotein; Cholesterol; Duodenal ulcer; HDL; Helicobacter pylori; LDL; Triglycerides

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUODENUM ULCER; DYSPEPSIA; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STAINING; SYMPTOMATOLOGY;

ADULT; AGED; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; BIOPSY; CHOLESTEROL; DUODENAL ULCER; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; RISK FACTORS; YOUNG ADULT;

EID: 47949109287     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802008132     Document Type: Article

References (35)

1. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;327:1170-1.
2. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:770-1.
3. Rauws EJ, Tytgat GN. Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin Gastroenterol 1995;9:529-47.
4. Uemuran N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:8298-332.
5. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9.
6. Tsang KW, Lam SK. Helicobacter pylori and extra-digestive diseases. J Gastroenterol Hepatol 1999;14:844-50.
7. Takashima T, Adachi K, Kawamura A, Yuki M, Fujishiro H, Azharul M, et al. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 2002;7:86-90.
8. Luo YH, Yan J, Mao YF. Helicobacter pylori lipopolysaccharide: biological activities in vitro and in vivo, pathological correlation to human chronic gastritis and peptic ulcer. World J Gastroenterol 2004;10:2055-9.
9. Fraser AG, Scragg RK, Cox B, Jackson RT. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J 2003;33:267-72.
10. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999;142:207-10.
11. Chimienti G, Russo F, Lamanuzzi BL, Nardulli M, Messa C, Di Leo A, et al. Helicobacter pylori is associated with modified lipid profile: impact on lipoprotein(a). Clin Bochem 2003;36:359-65.
12. Niemela S, Karttunen T, Korhonen T, Laara E, Karttunen R, Ikaheimo M, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996;75:573-5.
13. Hoffmeister A, Rothenbacher D, Bode G, Rersson K, Marz W, Nauck MA, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumonia or Cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001;21:427-32.
14. Regnstrom J, Jovinge S, Bavenholm P, Ericsson CG, De Faire U, Hamsten A, et al. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998;243:109-13.
15. Pilotto A, Rumor F, Franceschi M, Leandro G, Novello R, Soffiati G, et al. Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Age Ageing 1999;28:367-71.
16. Elizalde JI, Pique JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, et al. and the Study Group on Oesophageal and Gastric Diseases from The Spanish Gastroenterological Association. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 2002;16:577-86.
17. Everhart JE, Kruszon-Moran D, Perez-Perez G. Reliability of Helicobacter pylori and CagA serological assays. Clin Diagn Lab Immunol 2002;9:412-6.
18. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. and The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
19. Tepes B. Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy. Scand J Gastroenterol 2007;42:330-2.
20. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994;342:342-5.
21. Hala M, El-Zimaity T. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol Clin North Am 2000;29:63-9.
22. Chen XY, van der Hulst RW, Bruno MJ, van der Ende A, Xiao SD, Tytgat GN, et al. Interobserver variation in the histopathological scoring of Helicobacter pylori related gastritis. J Clin Pathol 1999;52:612-5.
23. Jacobs DR, Herbert B, Schreiner PJ, Sidney S, Iribarren C, Hulley S. Reduced cholesterol is associated with recent minor illness: the CARDIA study. Am J Epidemiol 1997;146:558-64.
24. D' Elios MM, Andersen LP. Helicobacter pylori inflammation, immunity and vaccines. Helicobacter 2007;Suppl 12:15-9.
25. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. National Heart, Lung and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
26. Ki Chul Sung , Eun Jung Rhee , Seung Ho Ryu , Sung Ho-Beck. Prevalence of Helicobacter pylori infection and its association with cardiovascular risk factors in Korean adults. Cardiology 2005;102:411-7.
27. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W, et al. Clinical relevance of the CagA, vacA and iceA status of Helicobacter pylori. Gastroenterology 1998;115:58-66.
28. Lamarque D, Peek RM Jr. Pathogenesis of Helicobacter pylori infection. Helicobacter 2003;8 Suppl 1:21-30.
29. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-a, interleukin-1a, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-9.
30. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF-alpha, LT-alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000;1:185-90.
31. Mitchell SA, Grove J, Spurkland A, Boberg KM, Fleming KA, Day CP, et al. and the European Study Group of Primary Sclerosing Cholangitis. Association of the tumour necrosis factor alpha-308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-94.
32. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, et al. Clinical presentation in relation to diversity within the Helicobacter pylori Cag pathogenicity island. Am J Gastroenterol 2002;97:2231-8.
33. Kunstmann E, Epplen C, Elitok E, Harder M, Suerbaum S, Peitz U, et al. Helicobacter pylori infection and polymorphisms in the tumor necrosis factor region. Electrophoresis 1999;20:1756-61.
34. Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID. Association of the TNF-α 308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002;10:401-7.
35. Zhao SP , Dong SZ. Effect of tumor necrosis factor alpha on cholesterol efflux in adipocytes. Clin Chim Acta 2007; Epub ahead of print.